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Abstract
Background: For osteoporotic femoral neck fractures, suitable bone-implant stability is critical for pain relief, early
return to daily activities and reduction of complications. Teriparatide (parathyroid hormone [PTH1-34]) can improve
bone-implant stability in some basic studies. However it’s use in osteoporotic femoral neck fractures treated by
cementless hemiarthroplasties for the beneficial effects on bone-implant stability is sparse in the literature. The aim
of this study was to determine if post-operative teriparatide administration can reduce femoral stem migration and
improve early functional recovery and health-related quality of life (HRQoL).
Methods: Between 2010 and 2014, patients with osteoporotic femoral neck fracture who underwent cementless
bipolar hemiarthroplasty were included into this retrospective cohort study. Group A included patients treated
with cementless bipolar hemiarthroplasty only; Group B patients had additional teriparatide. Demographic data,
complications, radiographic and functional outcomes as well as health-related quality of life (HRQoL) were
compared.
Results: There were 52 hips in group A (no teriparatide) and 40 hips in group B (patient who received teriparatide).
The subsidence of the femoral stem tended to be significantly decreased in the teriparatide group at 6 and 12 weeks
post-operatively (p = 0.003 and p = 0.008, respectively). The Harris Hip Score (HHS) increased significantly from
pre-operation to 6 weeks post-operatively and thereafter up to one year in both groups. However, there were no
significant differences in terms of subsequent fracture, mortality, HHS, and HRQoL between two groups during
the entire study period.
Conclusions: Teriparatide significantly reduces the subsidence of the cementless femoral stem in elderly patients
in the early post-operative period, but this benefit does not reflect better functional outcomes and HRQoL.
Further prospective randomized large-scale cohort study is warranted for evidence-based recommendations.
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Background
Femoral neck fracture is one of the most common
osteoporotic hip fractures [1]. Displaced femoral neck
fracture has been treated traditionally with cemented or
cementless hemiarthroplasty, with the goal of accom-
plishing pain relief and early recovery of daily activities,
which are critical for avoiding complications [2]. Cement-
less hemiarthroplasty has gained substantial popularity in
past decades as it helps solve problems pertaining to
cemented implants [3]. Achieving immediate stability of
the implant is vital for the success of cementless hemiar-
throplasty. However, decreased bone regenerative capacity
and poor bone stock may affect biologic fixation in elderly
patients [4].
Bisphosphonate (BP) has been demonstrated to possess
anti-fracture efficacy, preventing peri-prosthetic bone loss
[5] and lowering the risk of revision surgery after hip
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arthroplasty [6]. Recent results with the use of zoledronic
acid, a long-acting BP, in reducing migration of the fem-
oral stem have been encouraging [7, 8]; however, the inci-
dence of subsidence of the femoral stem remains high
among the elderly [7]. Teriparatide (parathyroid hormone
[PTH1-34]), approved by the U.S. Food and Drug Admin-
istration (FDA) in 2002, promotes the active building of
bone mass via stimulation of the proliferation and dif-
ferentiation of osteoprogenitor cells [9]. Recent animal
studies reveal an acceleration of fracture healing and
improvement of bone-implant stability in teriparatide-
treated animals [10]. In some human trials, teriparatide
appears to enhance fracture healing [11], accelerate
lumbar postero-lateral fusion [12], lessen the risk of
pedicle screw loosening [13], and increase the purchase
of the pedicle screws to the bone [14].
In theory, the positive impact of teriparatide on bone-
implant stability is important for an early return to daily
activities and reducing morbidity and mortality. This
retrospective study was aimed to determine if post-
operative teriparatide administration can reduce femoral
stem migration and improve early functional recovery and
health-related quality of life (HRQoL). Additional correl-
ation analyses were also conducted to determine the role
of supplementary teriparatide in reducing complications
and mortality in osteoporotic femoral neck fracture.
Methods
Clinical and demographic data
This retrospective study was approved by the Ethics
Committee and Institutional Review Board of the Chang
Gung Memorial Hospital (98-1038B), and all patients
provided signed informed consent.
All patients who underwent surgery for osteoporotic
femoral neck fracture at our institution since 2010 were
routinely entered into the osteoporosis management
program. Pharmacologic management, including calcium
and vitamin D supplements, anti-resorption drugs and
osteo-anabolic drugs, was offered. The merits, disadvan-
tages, and risks of osteoporosis treatment were based on
the International Osteoporosis Foundation (IOF) Guide-
lines for Osteoporosis Treatment [15] and were explained
to the patients. The choice of osteoporosis treatments was
decided by the patients themselves. Drug use information
was included in the computerized database.
We manually reviewed patient records in our database
to identify all patients who met the indication of teripara-
tide treatment (based on IOF Guidelines for Osteoporosis
Treatment [15]). To minimize surgeon-related confounding
factors, all cementless bipolar hemiarthroplasties were
performed by the same surgeon. All patients underwent
standardized hemiarthroplasty via a direct lateral ap-
proach. On the basis of the standard of care following
cementless hemiarthroplasty, the patients were encouraged
to ambulate with partial weight-bearing as soon as possible
after surgery. To minimize implant-related confounding
factors, the patients were treated with the same prosthesis
(PROFEMUR® Z hip stem, Wright Medical Technology,
Inc. Canadian). The stem had a double-tapered design with
grit-blasted surface processing and a rectangular shape that
fit at the metaphyseal-diaphyseal junction and proximal
diaphysis (Fig. 1a). To minimize drug-related variables,
patients who received anti-osteoporotic drugs before
surgery were excluded.
Patients with (1) a minimum follow-up of <12 months;
(2) multiple fractures, pathologic fractures, previous ipsi-
lateral hip or femur surgery, or fracture of the contralat-
eral hip; (3) musculoskeletal conditions that altered bone
conditions, like arthrogryposis multiplex congenita, polio-
myelitis, cerebral palsy, developmental abnormality, and
Down syndrome; (4) contraindication to the use of teri-
paratide; (5) complications related to teriparatide use, such
as generalized weakness and hypercalcemia; (6) minimum
teriparatide treatment course of <12 months; (7) inability
to ambulate pre-operatively; and (8) incomplete medical
records, radiographic analyses, and clinical functional as-
sessments, were excluded.
The patients were then divided into two subgroups:
those who received only calcium and vitamin D supple-
ments (600 mg of calcium and 800 international units
(IU) of vitamin D3 per day) (Group A) and those who
post-operatively received teriparatide and calcium and
vitamin D supplements (Group B). To determine adequate
sample size, a priori power analysis using the hypothesis
test with a power of 80 % and significance of 0.05 was per-
formed. Based on Friedl et al. [7], a pre-study sample size
calculation of 24 patients was required in each group to
detect a difference in implant migration of 0.5 mm/yr with
a power of 80 % at a 5 % significance level. According to
Achten et al. [16], 28 hips were required per group to de-
tect a difference of 10 points in the Harris Hip Score
(HHS) (estimated Standard deviation of 13). The cut-off
value was selected because a difference of 10 points was
suggested as the minimal clinically important difference.
Assessments
Radiographic assessment
All patients enrolled in this study were assessed by
radiographic examination, including antero-posterior
(AP) views of the pelvis and lateral views of the affected
hip pre-operatively, immediately after surgery and post-
operatively at 6 and 12 weeks, 6 and 12 months, and
then yearly. Radiographic evaluation of the hip pros-
thesis was performed with each standard pelvis AP and
lateral projection according to the system described by
Engh, Massin, & Suthers [17] and Johnston et al. [18].
Using post-operative radiographs, we recorded the position
of the femoral stem (valgus, neutral or varus), implant
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migration (Fig. 1), femoral stem-canal ratio (Fig. 2) [19],
radiolucent lines around the prosthesis, and pedestal for-
mation of the unstable stem. A stem migration of 0.6 mm
was considered a clinically important difference and was
defined as femoral stem subsidence, based on Thomas
Baad-Hansen et al. [20].
Bone mineral density (BMD) of the opposite hip was
measured using the Hologic DXA QDR 4500 (Hologic
Inc., Waltham, MA) after surgery. The radiographic as-
sessments and BMD of the opposite hip were reviewed
and analyzed by an independent surgeon who was
blinded to the groupings and patient demographic data.
Intra-observer reliability was assessed according to the
method described by Konigsberg et al. [21], and rated as
good to very good.
Functional assessment
Pre-operative surgical risk was categorized according to
the classification of the American Society of Anesthesiol-
ogists (ASA). Functional assessments including the HHS
and Short-Form-12 (SF-12) were performed at pre-injury
and at post-operative 3, 6, 9, and 12 months. The SF-12 is
a HRQoL scale composed of 12 questions. Physical
Component Summary (PCS) and Mental Component
Summary (MCS) scores were estimated by the assignment
of different weights to the questions. A higher score was
related to a better outcome. All functional outcomes were
assessed by an independent observer who was also blinded
to the groupings and patient demographic data.
Complications and use of analgesics were recorded.
Any medical or surgical event that compromised the
clinical recovery of patients, such as wound infection,
pneumonia, urinary tract infection, venous thrombo-
embolism (VTE), neurovascular injury, fracture, disloca-
tion, implant malposition, implant size mismatch, or early
loosening, was defined as an adverse event. A relatively
poorer and slower functional recovery beyond 3 months
and an HHS score <80 were also categorized as adverse
events.
Statistical analyses
All data were collected and independently entered into a
Microsoft Excel spreadsheet by an independent observer.
Fig. 1 a Plain X-ray of the implanted femoral components taken immediately after surgery. The implant (PROFEMUR® Z) fitted at the metaphyseal-
diaphyseal junction and the proximal diaphysis. The vertical distance between the lateral shoulder of the prosthesis and the superior tip of the greater
trochanter on the radiograph was recorded as A; the distance from the lateral shoulder of the prosthesis to the distal tip of the prosthesis was recorded
as B. b Plain X-ray of the implanted femoral components taken on follow-up. When measuring subsidence, corrections were made using the ratio of
vertical distance between the lateral shoulder of the prosthesis to the distal tip of the prosthesis (B’/B). The corrected vertical distance between the
lateral shoulder of the prosthesis and the superior tip of the greater trochanter was calculated using the equation: A X (B’/B). The subsidence was
calculated as A’ – A X (B’/B)
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After the spreadsheets were re-checked for missing and il-
logical data, the data were copied into SPSS version 13.0
for Windows (SPSS Inc., Chicago, IL) and analyzed. Stu-
dent’s t test was used to compare the variables of age,
body mass index, hospital stay, BMD of contralateral hip,
femoral stem-canal ratio, follow-up time, subsidence of
stem, and functional results. Between-group comparisons
of continuous variables at each time point were analyzed
using the Mann-Whitney U test, while within-group
comparisons between time points and baseline values
were performed using the Wilcoxon signed-rank test.
Categorical data were analyzed using the chi-square
test and Fisher’s exact test, as appropriate. All data
were analyzed by an independent statistician who was
blinded to the grouping, patient demographic data, and
function outcomes. Significance was set at p < 0.05.
Fig. 2 Assessment of the femoral stem-canal ratio. A line was drawn along the lateral margin of the lateral cortex and extended, and then the
width between this line and the medial cortex was measured (C-D). Femoral stem-canal ratio was defined as the ratio of the width of the femoral
component to the width of the medullary canal (E-F/C-D). Satisfactory was recorded when the ratio was more than 80 %. Radiographic evaluation
originally appeared in J Bone Joint Surg Br 1993;75:6-13. E-F: the width of the femoral component
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Results
Between 2010 and 2014, 112 patients (112 hips) met our
inclusion criteria. However, 14 patients who used anti-
osteoporotic drugs prior to surgery and 6 with incom-
plete data were excluded, leaving 92 patients (92 hips),
including 52 in Group A (no teriparatide) and 40 in Group
B (treated with teriparatide), for further analysis. The mean
follow-up time was 38.4 months (range, 12–59 months).
There were no differences in age, body mass index, ASA
classification, hospital stay, BMD of the contralateral hip,
femoral stem-canal ratio, and follow-up time between the
two groups (Table 1).
There was no difference between complications of the
two groups, except for subsidence rates (p = 0.028). A
summary of complications during the 12-month follow-
up revealed no deep wound infection, VTE, intra-
operative peri-prosthetic fracture, early loosening of the
femoral stem, or dislocation had occurred in either group
(Table 2). Both groups showed similar findings with regard
to superficial wound infection, pneumonia, urinary tract
infection, and post-operative peri-prosthetic fracture.
Six patients in Group A and four patients in Group B
died during the follow-up period due to reasons unrelated
to the operation (p = 0.545). The overall complication
rate between the two groups was significantly different
(p = 0.020) (Table 2).
Twenty-three patients (13 in Group A and 10 in
Group B) were excluded from the final analysis: ten pa-
tients died (6 in Group A and 4 in Group B), one had
post-operative peri-prosthetic fracture (Group B), and 12
had sustained subsequent fracture, including vertebral
fracture in 6 patients (4 in Group A and 2 in Group B),
hip fracture in 2 (one in Group A and one in Group B),
and wrist fracture in 4 (2 in Group A and 2 in Group B)
(Table 3). Patients who sustained peri-prosthetic fracture
and subsequent fracture were further excluded because
there would be different rehabilitation protocols and in-
fluences on outcome assessment. The remaining 69 pa-
tients (39 in Group A and 30 in Group B) were included
in the final analysis.
In the radiographic analysis, subsidence of the stem
in Group A significantly increased up to −1.0 ± 0.9 mm
and −1.3 ± 1.2 mm at 6 and 12 weeks, respectively
(Fig. 3). However, the migration pattern reached a plateau
at 6 and 12 months. In the final analysis, all implants
showed stable osteo-integration without evidence of fur-
ther migration. There were no radiolucent lines at the
prosthesis-bone interface and no pedestal formation in
any stem in either group. The HHS increased significantly
from pre-operation to 6 weeks post-operatively and there-
after up to one year in both groups. The differences in
scores, however, did not achieve statistical significance be-
tween the two groups throughout the study period
(Table 4). The two groups did not differ in SF-12 (PCS)
and SF-12 (MCS) during the entire study period (Table 5).
Discussion
The most important finding in this investigation is that
teriparatide use lessens the subsidence of cementless
femoral stems compared to non-use of teriparatide in
Table 1 Demographic Data of the Teriparatide and Control Groups
Parameters Group A Group B p value
N = 52 N = 40
Variables
Age at time of operation (yrs) 71.0 ± 8.3 72.1 ± 7.6 0.682
Body mass index (kg/m2) 26.9 ± 2.5 25.9 ± 3.1 0.693
ASA classification 0.829
ASA I - - -
ASA II 33 (63.5 %) 24 (60.0 %)
ASA III 19 (36.5 %) 16 (40.0 %)
Hospital stay (day) 7.3 ± 1.6 6.9 ± 1.6 0.464
BMD of contralateral hip (T-score) −4.3 ± 1.2 −4.2 ± 1.0 0.908
Femoral stem-canal ratio (%) 88.3 ± 5.2 87.6 ± 5.3 0.620
Follow-up (months) 27.1 ± 7.3 26.2 ± 7.4 0.650
Group A: patients without supplementary pharmacologic treatment
Group B: patients treated with teriparatide
Values are shown as mean (standard deviation) or as the n (%)
p-values for between-group comparisons were determined by the chi-squared
test and Fisher’s exact test for categorical variables and Student’s t test for
continuous variables
*Statistically significant (p < 0.05)
Table 2 Post-operative Complications in the Teriparatide and
Control Groups
Parameters Group A Group B p value
N = 52 N = 40
Variables
Superficial wound infection 2 (3.8 %) 1 (2.5 %) 0.598
Deep wound infection 0 0 -
Pneumonia 2 (3.8 %) 1 (2.5 %) 0.598
Urinary tract infection 2 (3.8 %) 1 (2.5 %) 0.598
Venous thrombo-embolism 0 0 -






0 1 (2.5 %) 0.435
Subsidence of the femoral stem 18 (34.6 %) 6 (15.0 %) 0.028*
Early loosening 0 0 -
Dislocation 0 0 -
Overall complications 30 (57.7 %) 14 (35.0 %) 0.020*
Group A: patients without supplementary pharmacologic treatment
Group B: patients treated with teriparatide
The values are given as the n (%)
p-values for between-group comparisons were determined by the chi-squared
test and Fisher’s exact test
*Statistically significant (p < 0.05)
Huang et al. BMC Musculoskeletal Disorders  (2016) 17:300 Page 5 of 9
the early post-operative period (6 and 12 weeks, post-
operatively). However, this benefit does not translate to
better functional outcomes and HRQoL. There was no
statistically significant difference between the two groups
in subsequent fracture and mortality.
Osteoporotic femoral neck fractures often contribute
to pain and immobility and lead to a loss of ability to
perform daily activities and a reduction in quality of life,
which are associated with high morbidity and mortality
[22, 23]. The annual number of these fractures world-
wide, as estimated by the IOF, will be as high as 4.6
million by 2025 and 6.26 million by 2050 [23]. This in-
jury is relatively common and is a serious clinical issue
affecting the elderly; it is a burden on individuals and
on the health-care system, as well as society in general
[1, 22, 23]. The primary treatment goals are pain relief,
improvement in mobilization and the prevention of
complications, which are of critical importance [1, 2].
However, this is also a challenge for orthopedic sur-
geons because of decreased bone regenerative capacity
and poor bone stock [4].
In treating osteoporotic femoral neck fractures, the
orthopedic surgeon is often the first physician to address
the injury and is in a unique position to make every ef-
fort to treat, prevent subsequent fractures, and minimize
the need for subsequent revision surgery [1, 2, 5–8].
Since bipolar hemiarthroplasty is commonly performed
in elderly patients with femoral neck fracture, post-
operative administration of anti-osteoporotic drugs is rea-
sonable and may play a valuable role in the treatment [1, 2].
Among these anti-osteoporotic drugs, BP is widely used
and has been demonstrated to prevent peri-prosthetic bone
loss [5, 8, 24], lower the risk of revision surgery after hip
arthroplasty [6], and reduce femoral stem migration [7, 8].
However, subsidence of the femoral stem is still higher in
elderly patients [7]. Moreover, concerns exist regarding BP-
induced osteonecrosis of the jaw, atypical femoral fracture,
and atypical peri-prosthetic fracture after long-term BP
treatment [25, 26].
Osteoblast activity may play an important role in
osteo-integration between bone and prosthesis [27]. The
anabolic agent teriparatide was approved by the U.S.
FDA in 2002, and was indicated for the treatment of
osteoporosis in men and in post-menopausal women [1].
Unlike anti-resorption drugs, teriparatide was found
to directly stimulate osteoblasts to increase trabecular
Table 3 Subsequent Fracture in the Teriparatide and Control
Groups during the 12-month Follow-up
Parameters Group A Group B p value
N = 52 N = 40
Subsequent fracture
Vertebral fracture 4 (7.7 %) 2 (5.0 %) 0.470
Hip fracture 1 (1.9 %) 1 (2.5 %) 0.683
Wrist fracture 2 (3.8 %) 2 (5.0 %) 0.587
Overall subsequent fractures 7 (13.5 %) 5 (12.5 %) 0.574
Group A: patients without supplementary pharmacologic treatment
Group B: patients treated with teriparatide
The values are given as the n (%)
p-values for between-group comparisons were determined by the chi-squared
test and Fisher’s exact test
*Statistically significant (p < 0.05)
Fig. 3 The migration pattern of the femoral components. The values are the mean for the teriparatide and control groups on follow-up intervals
immediately after surgery and at 6 and 12 weeks and 6 and 12 months. The subsidence of the stem was significantly decreased in the teriparatide
group compared to the control group at each time point. The distal migration of the stem reached a plateau phase at 6 months and 12 months
post-operatively in both groups. *p < 0.05, Mann-Whitney U test
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connectivity, cortical thickness, and bone mineral con-
tent in the peri-implant area, thereby accelerating
fracture healing and lumbar postero-lateral fusion and
improving bone-implant stability in treated animals [9, 10]
and in human trials [11–14]. In animal studies, finite
element analysis, and human trials, teriparatide showed
superiority over other BPs in improving femoral strength,
mechanical fixation of implants, and bone volume around
the implant [28, 29]. Despite the higher cost and relatively
poor compliance compared to other anti-osteoporotic
drugs, teriparatide may be a reasonable supplemental
treatment to enhance the stability of cementless femoral
stems in elderly patients after hemiarthroplasty for fem-
oral neck fracture. However, there is no published report
on the role of teriparatide in this situation.
The beneficial effects of teriparatide on implant fixation
have been reported recently [13, 14]. Ohtori S et al. [13]
prospectively studied 62 post-menopausal women and re-
ported that teriparatide increased the quality of lumbar
spine bone marrow and pedicle cortex. There was also a
significantly lower incidence of pedicle screw loosening in
the teriparatide group than in the risedronate or control
groups. Inoue et al. [14] reported a cohort study of 29
post-menopausal women who underwent fusion surgery
of the thoracic and/or lumbar spine and concluded that
pre-operative teriparatide treatment might be an option
for maximizing adherence of the pedicle screws to the
bone at the time of fusion surgery. This study retrospect-
ively analyzed the effect of teriparatide in preventing sub-
sidence of the cementless femoral stem in elderly patients
after bipolar hemiarthroplasty for femoral neck fracture.
Teriparatide significantly reduced femoral stem migration
compared to a control group of patients with calcium and
vitamin D supplements only.
Since peri-prosthetic bone loss is most pronounced in
the early post-operative period [30], decreases in bone
regenerative capacity in the elderly may impact osteo-
integration at the prosthesis-bone interface and further
contribute to subsidence of the femoral stem. The ab-
sence of osteo-integration of the femoral stem is related
to micro-movements at the prosthesis-bone interface.
In this study, the adequacy of fit and fill of the femoral
components in the medullary canal was examined, and
all femoral stems filled the canal by more than 80 %.
Moreover, patients were allowed protection against
weight-bearing due to a concern about subsidence that
could result from inadequate osteo-integration. However,
significant subsidence of the femoral stem still occurred in
the control group.
Improvements in osteo-integration at the prosthesis-
bone interface could allow elderly patients with femoral
neck fracture to return to their daily activities and re-
duce morbidity and mortality. However, this study
found no statistically significant differences in clinical
outcomes, HRQoL, subsequent fracture, and mortality
between those with and those without supplemental
teriparatide treatment. The most likely reason for this
is that migration of the prosthesis was limited in the
control group. The femoral stem subsided initially, but
stabilized at post-operative 12 weeks (Fig. 3).
This study has several limitations. First, it was a retro-
spective study, with all the inherent weaknesses and biases
of such a study design. Teriparatide is approved by the
Taiwanese FDA for treatment of osteoporosis only. Al-
though evidence from studies utilizing animal models in-
dicates teriparatide can improve osteo-integration at the
prosthesis-bone interface, this use in humans is “off label”
Table 4 Functional Outcomes Assessments at Different Time Intervals
Pre-injury Post-operation
3 months 6 months 9 months 12 months
HHS score
Group A 15.9 ± 9.1 56.2 ± 14.1 70.9 ± 13.0 77.9 ± 10.6 83.6 ± 7.5
Group B 15.4 ± 8.4 58.8 ± 10.1 71.1 ± 12.3 79.9 ± 9.4 81.5 ± 9.9
Group A: patients without supplementary pharmacologic treatment
Group B: patients treated with teriparatide
Values are shown as mean (standard deviation)
p-values for between-group comparison were determined by Student’s t test
Abbreviations: HHS, Harris hip score
*Statistically significant (p < 0.05)
Table 5 Health-Related Quality of Life (HRQoL) Assessments at
Different Time Intervals
Pre-injury Post-operation
3 months 6 months 9 months 12 months
SF-12 PCS
Group A 45.9 ± 8.5 28.2 ± 11.3 37.2 ± 10.8 39.2 ± 11.0 44.3 ± 11.6
Group B 46.2 ± 9.8 29.2 ± 11.3 38.1 ± 10.6 40.3 ± 9.9 45.0 ± 10.0
SF-12 MCS
Group A 59.2 ± 11.9 50.8 ± 11.1 53.7 ± 9.3 51.9 ± 10.6 54.2 ± 10.5
Group B 58.6 ± 10.9 51.7 ± 11.6 53.4 ± 9.5 52.4 ± 11.9 54.5 ± 10.9
Group A: patients without supplementary pharmacologic treatment
Group B: patients treated with teriparatide
Values are shown as mean (standard deviation)
p-values for between-group comparison were determined by Student’s t test
Abbreviations: HHS, Harris hip score
*Statistically significant (p < 0.05)
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and it is difficult to obtain approval for a prospective study
from the Ethics Committee and Institutional Review
Board. Second, the patient number was small. Patients
who took anti-osteoporotic drugs prior to surgery were
excluded to avoid the confounding factors of medication.
A single surgeon performed all hemiarthroplasties and the
same post-operative rehabilitation protocol was used. The
same prosthesis was implanted to avoid implant-related
confounding factors. The strict inclusion criteria were
meant to limit the study variables, but this also reduced
the numbers of subjects and limited the power of the
study to detect clinically significant differences. Although
adequate sample sizes were determined to detect differ-
ences in subsidence of the femoral stem [7] and HHS [16],
this study still may be underpowered to demonstrate sig-
nificant differences. Third, in treating osteoporotic femoral
neck fractures, the orthopedic community is divided be-
tween those using cementless hemiarthroplasty and those
using cemented hemiarthroplasty. In order to avoid
implant-related confounding factors, the current study
focused on treatment with cementless hemiarthroplasty.
Thus, the findings cannot be applied to teriparatide treat-
ment with cemented hemiarthroplasty. Fourth, there
are two different recombinant PTHs (PTH1-34 and
PTH1-84), but only teriparatide (recombinant PTH1-34)
is available in Taiwan. Although recombinant PTH1-84
also has had a clinical effect on fracture healing in post-
menopausal women [31], similar results with its use
cannot be assumed. There are also no comparative
studies of the anabolic effects of the two drugs. Last, al-
though differences between the two groups got statistical
significance, differences between mean value of subsidence
in the two groups is only about 0.7 mm. Clinical import-
ance of this difference is limited. Meanwhile, measure-
ments of the X-ray can not be so accurate, and this will
also reduce the importance of the difference.
Conclusions
This study found a significant reduction of subsidence of
the cementless femoral stem in elderly patients with
femoral neck fractures who were provided teriparatide
treatment. But teriparatide provided no significant bene-
fits in terms of clinical outcome, HRQoL, subsequent
fracture, and mortality. Further prospective randomized
large-scale cohort studies are warranted to determine if
the reduction in femoral stem subsidence will translate
into significantly superior clinical outcomes and HRQoL,
as a basis for evidence-based recommendations.
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